19 Mar

Exploring Analysts’ Views on GlaxoSmithKline

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts have set GlaxoSmithKline’s (GSK) 12-month consensus target price at $44.33, 9.48% higher than the stock’s closing price on March 18. Analysts’ consensus recommendation for the stock is a “buy.” In 2019, analysts have revised the company’s target price upward once, from $44.00 in January to $44.33 in March.

To learn about GlaxoSmithKline’s key growth drivers this year, read What Are the Key Growth Drivers for GlaxoSmithKline in 2019?

Exploring Analysts’ Views on GlaxoSmithKline

Of the four analysts covering GlaxoSmithKline, two have given it “strong buys,” and two have given it “holds.” The highest target price estimate for the company is $46, and the lowest is $42.

On March 18, GlaxoSmithKline closed at $40.49, 0.34% lower than its previous closing price, 12.07% higher than its 52-week low of $36.13, and 4.41% lower than its 52-week high of $42.36. The company’s market cap is $98.86 billion.

Based on its closing price on March 18, GlaxoSmithKline has reported returns of 1.02% in the last week, -0.91% in the last month, and 6.72% in the last quarter. The company has reported returns of 2.95% in the last half year, 9.67% in the last year, and 5.97% year-to-date.

Revenue and EPS estimates

Analysts expect GlaxoSmithKline’s revenue to see YoY (year-over-year) changes of -2.40% to $9.81 billion in the first quarter, 0.74% to $10.01 billion in the second quarter, 2.34% to $10.79 billion in the third quarter, and 1.47% to $10.70 billion in the fourth quarter of 2019. Analysts also expect the company’s non-GAAP (generally accepted accounting principles) EPS to see YoY changes of -4.35% to $0.66 in the first quarter, -13.92% to $0.68 in the second quarter, -10.87% to $0.82 in the third quarter, and -6.29% to $0.76 in the fourth quarter.

Analysts expect GlaxoSmithKline’s revenue to see YoY rises of 1.69% to $41.78 billion in 2019, 1.92% to $42.58 billion in 2020, and 3.69% to $44.16 billion in 2021. Analysts also expect the company’s non-GAAP EPS to see YoY changes of -5.82% to $2.92 in 2019, 6.50% to $3.11 in 2020, and 16.27% to $3.62 in 2021.

Latest articles

German chip maker Infineon Technologies has reportedly raised 1.55 billion euros (~$1.74 billion) in capital by selling its shares to fund its acquisition of Cypress Semiconductor (CY). Infineon has sold ~113 million new shares at 13.70 euros each.

As of June 18, Dunkin’ Brands (DNKN) was trading at $80.07, an 8.9% rise since reporting its first-quarter earnings on May 2. Also, DNKN was trading at a premium of 29.8% from its 52-week low of $61.69 and a discount of 1.6% from its 52-week high of $81.40.

19 Jun

Are Lower Oil Prices Weighing on ExxonMobil Stock?

WRITTEN BY Maitali Ramkumar

ExxonMobil (XOM) stock has fallen 7.1% in the second quarter so far. Let's review ExxonMobil's stock performance in comparison to oil price changes and equity market movements in the quarter.

19 Jun

As Facebook Unveils Libra, MSFT and CRM Join a Blockchain Group

WRITTEN BY Mayur Sontakke, CFA, FRM

On June 18, Facebook (FB) launched Libra, its own cryptocurrency. On the same day, CoinDesk published another piece of blockchain news that didn’t receive as much fanfare as Facebook’s Libra news. Was the timing a coincidence? We think not.

Uber Technologies (UBER) has picked Melbourne as another test site for its flying taxi service known as UberAir. The Australian city is the first international test site Uber has chosen for its flying taxi service. The addition of Melbourne brings the number of test locations Uber has picked for its UberAir service to three.

Lyft (LYFT) and Uber Technologies (UBER) are pushing back against California legislation that would require them to recognize their drivers as employees rather than independent contractors. The legislation would require companies like Lyft to give their drivers the compensation and benefits spelled out under California’s employment regulations.

172.31.59.107